TLR7 and influenza: In another study, administration of a licensed quadrivalent inactivated influenza vaccine adjuvanted with RIG-I (SDI-nanogel) and a TLR7/8 agonist (imidazoquinoline) enhanced the antibody and T cell responses and was correlated with protection against lethal influenza virus infection [125].